LCGC North America
In advance of Pittcon 2018, leading scientists-Ronald Majors, Richard Henry, John W. Dolan, Zachary S. Breitbach, and Daniel W. Armstrong-who will be speaking at the LCGC awards symposium give us a preview of their talks.
High performance liquid chromatogrpahy (HPLC) or liquid chromatography–mass spectrometry (LC–MS) methods are widely preferred for the analysis of both small and large compounds. As target molecules increase in size, maintaining optimum separation performance requires a change to larger column pore diameters. Giddings (1) cautions that if pores become too small for the sample, larger molecules lose freedom of movement and good access to stationary phase. When sample components approach the pore diameter too closely, poor equilibration and a slow diffusion rate within the pores may cause a sharp reduction in column retention and efficiency. Available data suggest that performance loss may become noticeable when target molecules are larger than about 10% of the mean particle pore diameter (a molecule-to-pore ratio of 0.1).
Commercial silica particles in HPLC columns typically have broad pore distributions to accept and separate a useful range of solutes up to a size limit determined by analyte molecular weight (MW) and average particle pore diameter. Unfortunately, a complex relationship exists between MW and size. Molecules with the same MW can have different shapes and sizes in solution. Hydrodynamic volume-the solution space that a molecule occupies-determines whether a molecule can gain access to column pore structure. Since size-exclusion chromatography (SEC) directly measures hydrodynamic volume, it can be a very convenient way to estimate whether a good size match exists between samples and columns.
Figure 1 shows a calibration plot for 12 molecules with increasing size created with an SEC 150-Å column. A small-pore HPLC column could not possibly analyze this sample in reversed-phase mode because the MW and size range is much too large for good performance with larger components. It is clear from Figure 1 that only uracil (point 12) and other very small molecules have complete access to the total pore volume (VM) of this 150-Å silica column. Fortunately, a certain amount of overlap between exclusion mode and retention modes can usually be tolerated, and good performance can still be achieved for molecules that are eluted in the lower MW half of the calibration curve (points 8–11). Figure 2 shows HPLC results in reversed-phase mode with 90-Å and 160-Å silica C18 columns for a sample containing bovine insulin and other small proteins. Bovine insulin (MW 5700) is about 40% excluded from the pore volume of 150-Å silica in the calibration plot. The 90-Å pores are clearly too small for the larger peptides, which would be greater than 50% excluded from the pores in Figure 1. Even the two insulin peaks experience some loss of performance because they become sharper with greater retention when the C18 column is changed to 160-Å pore silica. Note that the entire peptide sample shows more retention on 160-Å C18 even though that column has lower surface area and therefore less stationary phase. When larger molecules are partially excluded from the pore structure, column retention is determined by accessible stationary phase at a reduced level of column efficiency.
Figure 1: Calibration curve for SEC. Column: 30 cm × 4.6 mm, 3-µm Sepax Zenix SEC-150; mobile phase: 0.2 M potassium phosphate, pH 7.0; flow rate: 0.25 mL/min; pressure: 66 bar; column temperature: 25 °C; detection: UV absorbance at 215 and 280 nm; injection volume: 0.5 µL. (Data provided by AMT.)
The full paper to be presented at Pittcon 2018 in Orlando will review what is known about pores, how they compare in size to solutes, how to make early column selection decisions to maximize the chances for good separation, how to use SEC to recognize when a mismatch may exist between compound size and column pore size, and how to solve problems if poor performance is observed. Improved separations for very large molecules will be shown with new commercially available columns, and further improvements may be possible through a better understanding of the internal pore structure of HPLC and UHPLC columns.
Figure 2: Small protein and large peptide separations obtained using columns with (a) 90-Å and (b) 160-Å pore sizes. Peak widths in minutes are shown above each peak. Columns: (a) 100 mm × 4.6 mm, 2.7-µm, 90-Å Halo C18 (surface area: 135 m2/g), (b) 100 mm × 4.6 mm, 2.7-µm, 160-Å Halo ES-C18 (surface area: 90 m2/g); mobile-phase A: water with 0.1% trifluoroacetic acid; mobile-phase B: acetonitrile with 0.1% trifluoroacetic acid; gradient: 25–42% B in 10 min; flow rate: 1.5 mL/min; temperature: 30 °C; detection: UV absorbance at 215 nm. Peaks: 1 = ribonuclease A (13,700 g/mol), 2 = bovine insulin (5733 g/mol), 3 = human insulin (5808 g/mol), 4 = cytochrome c (12,400 g/mol), 5 = lysozyme (14,300 g/mol).
(1) J.C. Giddings, Unified Separation Science (Wiley, Hoboken, New Jersey, 1991), chap. 2.
Richard Henry
Richard Henry is an independent consultant in State College, Pennsylvania. Stephanie A. Schuster is Application and Quality Manager with Advanced Materials Technology, Inc., in Wilmington, Delaware.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.